Pharmacokinetic interactions between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV [Interacciones farmacocineticas entre Telaprevir y Atazanavir no potenciado con ritonavir en pacientes coinfectados por el VIH y el VHC genotipo 1 en tratamiento para la hepatopatía cronica por el VHC]

Trial Profile

Pharmacokinetic interactions between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV [Interacciones farmacocineticas entre Telaprevir y Atazanavir no potenciado con ritonavir en pacientes coinfectados por el VIH y el VHC genotipo 1 en tratamiento para la hepatopatía cronica por el VHC]

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Atazanavir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Mar 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 26 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01818856).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top